U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07199933) titled 'Diacerein in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease' on Sept. 08.
Brief Summary: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic progressive liver disease in China, posing a significant risk for hepatic decompensation, cardiovascular disease (CVD), chronic kidney disease (CKD), and various malignancies. It severely impacts patient quality of life and life expectancy, creating a substantial socioeconomic burden. Currently, no safe and effective drug exists to reverse MAFLD.
Rhubarb (Da Huang), a classic Traditional Chinese Medicine (TCM) herb for liver disorde...